JPMorgan analyst Sebastian Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps an Overweight rating on the shares. The firm views the company’s Q4 report as solid.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies: Sustained MRD Growth, Pricing Power, and Strategic Positioning Support Buy Rating and Premium Valuation
- Adaptive Biotechnologies: Strong MRD Momentum, Enhanced 2026 Outlook, and Clear Path to Profitability Support Buy Rating
- Adaptive Biotechnologies reports Q4 EPS (9c), consensus (18c)
- Adaptive Biotechnologies sees FY26 operating expenses $350M-$360M
- Is ADPT a Buy, Before Earnings?